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Background: In this retrospective study, we investigated the efficacy and safety of radioimmunotherapy with
90Yttrium- ibritumomab tiuxetan (90Y-RIT) in 9 patients with recurrent follicular lymphoma (FL) who were treated
in a consolidation setting after having achieved complete (CR) or partial remission (PR) with Fludarabine,
Cyclophosphamide and Rituximab (FCR).
Methods: The median age was 63 years (range 46–77). All patients were relapsed with histologically confirmed
CD20-positive (grade 1 or 2) FL, at relapse they received FCR every 28 days: F (25 mg/m2x 3 days), C (1 gr/m2 day 1)
and R (375 mg/m2 day 4) for 4 cycles. Those who achieved at least a PR with <25 % bone marrow involvement were
treated with 90Y-RIT 11.1 or 14.8 MBq/Kg, at 3 months after completing FCR. Patients underwent a further restaging
at 12 weeks after 90Y-RIT with a total body CT scan, FDG-PET/CT and bilateral bone marrow biopsy.
Results: Nine patients completed the treatment: FCR followed by 90Y-RIT (6 patients at 14.8 MBq/Kg, 3 patients at
11.1 MBq/Kg). After FCR, 7 patients obtained CR and 2 PR; after 90Y-RIT 2 patients in PR converted to CR 12 weeks
later. With a median follow up of 95 months (range 20–114) since FCR and 88 months (range 13–104) since 90Y-RIT 3
deaths were not related to lymphoma; all 3 deceased patients obtained CR before 90Y-RIT and died still in CR. The
median overall (OS) and progression free survival (PFS) have not been reached, in this analysis both OS or PFS are
67 % at 7.5 year. The most common grade 3 or 4 adverse events were hematologic.
Conclusions: These results confirm the long term efficacy and safety of 4 cycles of FCR followed by 90Y-RIT in
relapsed grades 1 and 2 FL and suggest that this regimen could be a therapeutic option for this setting of patients,
specially at age of 60–75 with no unexpected toxicities.
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Table 1 Patient characteristics
Patients (n = 9)
Male/Female 3/6
Median Age (Range) 63 (46–77) years







10 % to ≤25 % 2







Previous therapy including rituximab
No 2
Yes 7




Pisani et al. Experimental Hematology & Oncology  (2015) 4:17 Page 2 of 6Introduction
Most cases of follicular lymphoma are characterized by
recurrence of disease. There is usually a pattern of
repeated remissions and relapses until patients become
refractory to treatment. The duration of remissions be-
comes shorter with repeated induction attempts. Trans-
formation to more aggressive non-Hodgkin lymphoma
(NHL) occurs in 15 % to 50 % of the patients at 5 years.
Therefore, it is important to have many treatment op-
tions: combination chemotherapy, radiation, immuno-
therapy, radioimmunotherapy and myeloablative therapy
with stem-cell rescue for some patients with good per-
formance status and responsive disease to overcome the
development of resistance. A number of cytotoxic agents
in combination are active in this patient population. The
fludarabine, cyclophosphamide and rituximab (FCR)
regimen provided encouraging results as initial or
salvage therapy in patients with CLL or indolent NHL
[1, 2]. Radioimmunotherapy is also an excellent modality
in the treatment of NHL; the target antigen, radionuclide
emission properties and chemical stability of radioimmu-
noconjugates are important factors that contribute to
the effectiveness of RIT. 90Y can deliver a high beta en-
ergy to tumor (2–3 MeV) and 90Yttrium- ibritumomab
tiuxetan (90Y-RIT ) consists of the anti-CD20 monoclo-
nal antibody ibritumomab (an IgG1k antibody which is
the murine parent immunoglobulin to rituximab) cova-
lently bound to the chelating agent tiuxetan and radiola-
beled with 90Y.
The phase III FIT trial (First-line Indolent Trial), en-
rolled 414 patients with stage III or IV who had attained
a CR or PR after induction chemotherapy. It showed
that consolidation of first remission with 90Y-RIT was
highly effective with no unexpected toxicities, producing
a statistically significant longer time to progression in
both PR and CR patients groups. In the last update of
the trial the median PFS has not yet been reached
(>7.9 years) for patients in the 90Y-RIT arm and 4.9 years
in control arm [3–5]. Furthermore, several phase II trials
show high rates of conversion from PR to CR and sig-
nificant improvements in PFS [6–14] using consolidation
therapy with 90Y-RIT obtained, after initial treatment.
90Y-RIT also has been reported to be effective in patients
with relapsed or refractory FL [15–17]. Here, we report
updated long–term efficacy and toxicity results of
90Y-RIT consolidation in 9 patients relapsed with grade 1




In this retrospective analysis 9 patients had received
4 cycles of FCR followed by 90Y-RIT (6 patients at
14.8 MBq/Kg, 3 patients at 11.1 MBq/Kg). Baselinecharacteristics are presented in Table 1. The median age
was 63 years (range 46–77), all patients were relapsed
patients: 2 patients received a prior therapy, 5 patients re-
ceived 2 prior treatments and 2 patients received 3 regi-
mens. Seven patients were previously treated with
rituximab plus chemotherapy, 2 patients had no previous
rituximab treatment history, 1 patient received also high-
dose therapy followed by autologous stem cell transplant-
ation (Table 2).
Efficacy and safety
After 4 cycles of FCR 7 patients obtained CR and 2 PR,
2 patients in PR converted to CR after 90Y-RIT. In
February 2015, with a median observation period of
95 months (range 20–114) since FCR and 88 months
(range 13–104) since RIT, the median OS and the PFS
have not been reached, 6/9 patients were alive in CR
and current analysis has shown that either OS or PFS
are 67 % at 7.5 year (Fig. 1). Grade 3 or 4 neutro-
penia occurred in 8/9 patients treated with FCR and
in 9/9 patients assessable after 90Y-RIT. Subsequently
to radioimmunotherapy the median neutrophil nadir
Table 2 Clinical characteristics
Patients n Sex/Age (y) Previous treatment Response to FCR Response to RIT Follow up (mo) since RIT
1 F/68 CHOP/R,radiotherapy CR CR 104 alive in CR
2 F/66 Radiotherapy, CHOP/R CR CR 88 alive in CR
3 F/57 CHOP/R PR CR 99 alive in CR
4 F/67 CHOP/R, radiotherapy CR CR 13 dead in CR
5 M/46 CHOP/like, ASCT, IFN maintenance for 24 months PR CR 83 alive in CR
6 F/61 MACOPB/R CR CR 92 alive in CR
7 M/69 CHOP, FM/R, CyDex/R CR CR 30 dead in CR (t-MDS)
8 M/57 Chlorambucil, MACOPB/R CR CR 32 dead in CR
9 F/77 Chlorambucil, radiotherapy CR CR 99 alive in CR
CHOP cyclophosfamide, doxorubicin, vincristine, prednisone; R Rituximab; MACOPB Methotrexate, Doxorubicin, cyclophoshamide, vincristine, prednisone, bleomycin;
ASCT autologous stem cell transplantation; IFN alpha interferon, FM fludarabine, mitoxantrone; Cy Dex cyclophosphamide, dexamethasone; t-MDS treatment-related
myelodysplastic syndrome
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the median platelet count nadir was 49 × 109/ L
(range 17–80 × 109/ L) at week 5. The median dur-
ation nadir for both neutrophils or platelets was
14 days. One patient developed herpes zoster infec-
tion after 8 months following valacyclovir discontinu-
ation; another patient developed fungal infection.
Both infections disappeared after specific treatment.
One patient developed t-MDS (treatment-related
myelodysplastic syndrome) at 26 months after 90Y-
RIT. This patient before FCR and consolidation with
90Y-RIT had received 3 previous regimens: at diagno-
sis 6 courses of CHOP, at first relapse, 3 years later,
4 courses of FM/R (fludarabine, mitoxantrone plusFig. 1 Progression Free Survival from RITrituximab) and after 1 year at the second relapse the
patient received cyclophosphamide plus dexametha-
sone and rituximab, remaining in CR for 48 months.
The patient died at 73 years of age of sepsis during
support therapy for t-MDS. Other 2 patients died: 1
for acute renal failure and 1 for ictus cerebri.
Discussion
Cytotoxic chemotherapies lose efficacy with subse-
quent rounds of therapy in the retreatment of fol-
licular lymphoma, eventually leading to refractory
disease, however the question remains whether the
survival of patients with FL is improving with new
treatment regimens.
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with relapsed grade 1 and 2 FL, responding to FCR
regimen and consolidated with 90Y–RIT obtained a
significant high rate of response with 100 % of CR
and acceptable toxicity. The conversion from PR to
CR was already shown in the published phase III
study (FIT-study) in first-line FL [3, 4] and also in
phase II studies [5–12] of consolidation with the
radioimmunotherapy agent 131 I-tositumomab after
first-line induction [19, 20] thus, confirming the abil-
ity of 90Y-RIT to improve responses also in patients
who are pretreated with rituximab based combination
therapy [3]; even if in our two patients there is no
proof that this conversion was due to RIT and not to
a late response to FCR. In the FIT study, close to
17 % of the patients in the control arm, converted
from PR to CR during watchful waiting [3], but our
2 patients who had higher risk of resistance already
being pretreated must be considered.
In our analysis, the OS at 2 years was 89 %, at 3 years
76 % and at 4 years 61 % and OS and PFS are 67 % at
7.5 years. In another study conducted on patients with
recurrent FL, treated with FCR, 75 % OS rate at 4 years
and 61 % PFS rate at 4 years were registered, but in that
study only 7 % of patients had been treated previously
with rituximab and furthermore no patients had received
combination treatment with chemotherapy plus rituxi-
mab [21]. Furthermore our results are in line with those
recently described in a Japanese study [22] on 94 pa-
tients with relapsed or refractory low grade B cell non-
Hodgkin lymphoma, among them 61 patients with grade
1 and 2 FL, treated with 90Y-RIT alone as salvage therapy
and showing a CR rate of 69 %. In the Japanese cohort,
during a median follow up of 46.5 months, the PFS rates
of the first 50 patients who had undergone ≤ 2 and ≥ 3
previous regimens, and for those who achieved CR com-
pared with those who did not were 38 and 11 months,
respectively; the number of previous regimens and CR
were statistically significant (p = 0.0011 and p < 0.0001,
respectively). In our study 7/9 patients underwent ≤ 2
previous regimens before FCR and all of patients
reached CR after 90Y-RIT with a PFS of 67 % at 7.5 years.
Regarding AEs no grade 3 or 4 anemia was noted
and no erythropoietic growth factors were used; there
was high incidence of grade 3 or 4 neutropenia and
thrombocytopenia but no platelet transfusions were
necessary and granulocyte colony-stimulating factors
were utilized in the majority of patients during FCR
treatment and in all of them after 90Y–RIT. Despite
the high incidence of grade 3 or 4 neutropenia, there
were no patients requiring hospitalization for infec-
tion. We registered a case of herpes zoster infection
after 8 months following valacyclovir discontinuation
that disappeared after retreatment, and a case of fungalinfection by conidiobolus, developed 10 months after
90Y-RIT and disappeared with itraconazole treatment.
Other previous studies have already shown the low
percentage of patients requiring hospitalization for
infections [3, 15] and a favorable safety profile [23, 24]. A
case of t-MDS with complex karyotype was diagnosed
26 months after 90Y-RIT consolidation: this patient re-
ceived 3 previous regimens before FCR plus 90Y-RIT and
as already mentioned the patient died of sepsis. This pa-
tient had been previously treated with topoisomerase II
inhibitors, alkylating agents and purine nucleoside
analogs. Czuczman et al. reported incidence of t-MDS
and t-AML (treatment-related acute myeloid leukemia)
after 90Y–RIT of 0.3 % per year after the diagnosis of
NHL and 0.7 % per year after treatment. Most patients
with t-MDS or t-AML had multiple cytogenetic aberra-
tions, commonly on chromosomes 5 and 7, suggesting
an association with previous exposure to chemotherapy.
In Czuczman study, these malignancies were diagnosed
at a median of 5.6 years (range 1.4 to 13.9) after the
diagnosis of NHL and 1.9 years (range 0.4 to 6.3) after
radioimmunotherapy [25]. The conclusion of this
study was that the annualized incidences of t-MDS
and t-AML were consistent with that expected in pa-
tients with NHL who had extensive previous chemo-
therapy and did not seem to increase after 90Y-RIT.
However, in the FIT study 8 patients who developed
MDS/AML were treated with 90Y-RIT, suggesting a
role played by 90Y-RIT in the risk of secondary
MDS/AML, thus it is reasonable to consider monitoring
these patients closely. Cytogenetic testing before treat-
ment with RIT may identify existing chromosomal ab-
normalities in previously treated patients, particularly
those who have been treated with alkylating agents and
purine analogs and would be at higher risk of developing
t-MDS or t-AML.
In our series, the other two deaths were not related
to progressive disease and all three deceased patients
obtained CR before 90Y-RIT and died still in CR; so
far the six survivors have maintained a high quality
of life without having to make many visits to the
hospital due to toxicity. Additional follow up is re-
quired to determine potential long-term AEs with
90Y-RIT consolidation. In our patients, the response
to 90Y-RIT was assessed by CT, bone marrow biop-
sies and also with FDG-PET. This imaging procedure
is useful to evaluate disease extension before treat-
ment and response to RIT in FL. A study has shown
that the post-90Y–RIT PET result is an independent
predictive factor of PFS [26].
Conclusions
This retrospective analysis of 9 relapsed grades 1 or 2 FL
heavily pretreated patients with median age 63 years
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90Y-RIT did not give rise to cumulative toxicity; it was
feasible, safe and yielded high OS and PFS in patients
with recurrent FL. Hematologic toxicity occurring with
FCR or with 90Y-RIT was clinically controllable and
acceptable in a population composed mainly of pa-
tients with a history of prior treatment using rituxi-
mab plus chemotherapy. With caution due to the
low number of patients, these results suggest that
this regimen could be an option used for the treat-
ment in this setting of patients, specially at age of
60–75. 90Y-RIT as consolidation appears to be best
suited to patients with low burden of disease and
may be more acceptable in those who are not candi-
dates for high dose therapy/transplant approaches.
Design and methods
The patients who were included in the current retro-
spective analysis had CD20+ histologically confirmed re-
lapsed grade 1 or 2 follicular lymphoma and had
received at least 1 prior treatment. In this single institu-
tion study, between August 2005 and July 2010, 9 pa-
tients at relapse had received 4 cycles of FCR:
fludarabine at a dose of 25 mg/m2 i.v. on days 1 to 3;
cyclophosphamide at a dose of 1 gr/ m2 i.v. on day 1
and rituximab at a dose of 375 mg/ m2 was given on day
4 of each cycle every 28 days. Patients were restaged
with CT scan, FDG PET/CT and bone marrow biopsies
after the last course of FCR, who had achieved at least a
partial remission with < 25 % bone marrow involvement
received, 12 weeks since the last course of FCR, 2 infu-
sions of rituximab 250 mg/ m2 one week apart, with the
first infusion administered alone and the second infusionFig. 2 Treatment schemafollowed immediately by 90 Y–RIT (14.8 MBq/Kg –
11 MBq/Kg), if the platelet number was between 100 x
109/ L and 149 x 109/ L, not exceeding a total of
1.184 MBq it was administered as a slow i.v. push over
10 min (Fig. 2). The patients were age ≥ 18 years, with
WHO performance status of 0 to 2 and the last chemo-
therapy with or without rituximab was administered
at least 3 months before start of FCR; no patient
under maintenance therapy with rituximab was con-
sidered. Before starting 90Y-RIT an absolute neutrophil
count ≥ 1.5 × 109 L, hemoglobin levels ≥ 9 gr/dl and a
platelet count ≥ 100 × 109 L were required. None of the
patients had central nervous system (CNS) involvement
and positive HIV. All patients provided an informed con-
sent according to institutional guidelines.
No real-time quantitative PCR (RQ-PCR) evaluation of
peripheral or marrow blood samples for bcl-2 t(14;18)
translocation was performed at baseline nor thereafter.
Safety was assessed by adverse events (AEs), with tox-
icity grading based on the National Cancer Institute
Common Toxicity Criteria (version 4.0), clinical labora-
tory evaluations, and physical examinations. Filgrastim
was administered when the neutrophil count was less
than 1×109/L and platelet support was planned for
eventual episodes of bleeding and platelet count less
than 15×109/L. In patients developing grade 4 neu-
tropenia or thrombocytopenia, the duration of cyto-
penia was measured from the first day of laboratory
evidence of grade 4 toxicity until the last day of
grade 4 toxicity without further support. OS was cal-
culated from the date of FCR treatment to the date
of death from any cause; OS was analyzed by using
the Kaplan-Meier method.
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